A Phase I/II Study of a 72-h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma. (Q36673831)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18521217%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

A Phase I/II Study of a 72-h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18521217%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18521217%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Crawley CR

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18521217%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Judson IR

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18521217%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Verrill M

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18521217%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Hill C

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18521217%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

1 January 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18521217%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18521217%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18521217%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

3-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18521217%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

149-154

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18521217%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 3.0 Unported

8 January 2020

copyright license

start time

1 January 1997

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395367

The clinical pharmacology of etoposide: an update

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395367

Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395367

Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395367

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395367

Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395367

Reporting results of cancer treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395367

Chronic daily administration of oral etoposide--a phase I trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395367

Mechanism of action of antitumor drug etoposide: a review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395367

Oral etoposide in treatment of advanced refractory sarcomas

30 September 2017

1 reference

12 December 2020

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

12 December 2020

VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group

1 reference

12 December 2020

High-performance liquid chromatography of etoposide in plasma and urine

1 reference

12 December 2020

A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity

1 reference

12 December 2020

Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

Identifiers

DOI

10.1080/13577149778236

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18521217%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18521217%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

PubMed publication ID

18521217

1 reference